Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

European Research Council grant · Running

uPSCale Scaling up iPSC Expansion and Differentiation using Recombinant Bioemulsions

Coordinator
Queen Mary University of London, United Kingdom
Runs
1 May 2025 to 31 October 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101189457

What the project is doing

In the project's own words, from its summary on CORDIS.

Advances in stem cell technologies have revolutionised cell therapy and advanced in vitro models, but remain limited by our ability to scale up and automate cell manufacturing. In particular, induced pluripotent stem cell (iPSC) expansion and differentiation require complex processing protocols that are preventing the wider deployment of associated technologies to the clinic and industry. Although solid and hydrogel microcarriers have displayed potential in addressing this challenge, they present hurdles to the processing and separation from cell products, leading to contamination of the generated cells, the poor control of their phenotype and high production costs.

Developing cost-effective, scalable, and regulatory-compliant platforms for culturing, differentiating and processing iPSCs, while circumventing reliance on solid substrates and microcarriers, remains critical for advancing cell manufacturing and will significantly impact the sustained growth of associated biotech markets. To mitigate contamination risks, streamline bioprocessing, and reduce associated costs, bioemulsions have emerged as promising alternatives.

Despite their demonstrated performance in a growing range of cellular contexts, current underpinning protein and polymer nanosheet technologies raise concerns regarding regulatory compliance, for broad application in regenerative medicine. We propose the engineering of recombinant protein nanosheets for the stabilisation of biomedical grade oil microdroplets, that will tackle these challenges and allow the production of bioemulsions in a scalable format, aligned with regulatory expectations.

The ability of the resulting bioemulsions to sustain the culture of iPSCs and their differentiation into defined lineages will be validated and this technology will be de-risked, in collaboration with industrial partners aiming to scale up iPSC technologies. This will allow the development of further IP that will support the exploitation of bioemulsions.

Topics

Who is involved

OrganisationCityCountryRole
Queen Mary University of LondonLondonUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI